• Share
  • Email
  • Print

Jonathan M. Barron

Associate
+1.212.536.3915
Fax +1.212.536.3901

Mr. Barron is a corporate and securities lawyer in the New York office of K&L Gates. His practice focuses on various corporate and securities law matters, including mergers and acquisitions, financing transactions, commercial contracts, and advising public companies on securities law compliance, securities offerings, and corporate governance. Mr. Barron’s practice also includes advising investment fund managers on a wide variety of transactions, including seeding arrangements, investment manager M&A transactions, and other corporate and finance-related matters.

Mr. Barron has represented a major financial institution in the negotiation of an exclusive co-branded credit card agreement. He has also advised borrowers and lenders on secured credit facilities, including one secured by IP held in a special purpose vehicle and others secured by solar renewable energy credits. He has represented private companies in preferred stock offerings and also public companies in various PIPE offerings.

Mr. Barron has worked extensively with clients in the generic pharmaceutical industry on U.S. and cross-border development, supply and other commercial contracts. On the M&A side, he represented an NYSE-listed pharmaceutical manufacturer in the acquisition of abbreviated new drug applications (ANDAs) and related assets, and an international pharmaceutical company which purchased ANDAs and related assets as part of an FTC ordered divestiture.

He has also advised clients on services, supply, and consulting agreements across various industries, including programmatic advertising, software development, and the Internet of Things (IoT).

In addition, Mr. Barron has represented private equity firms, service providers and portfolio companies on various corporate, finance and M&A matters.

Professional Background

During law school, Mr. Barron was a summer associate at K&L Gates.  Prior to law school, Mr. Barron was a mathematics teacher in New York City.

  • Advising US-listed companies and shareholders on Securities Act and Exchange Act compliance and various corporate governance matters
  • Advising a national television and radio media firm on commercial contract issues
  • Represented shareholders of a publicly traded optical retail company in a "going private" transaction
  • Represented Nasdaq and NYSE Amex-listed companies in conducting reverse stock splits
  • Assisted multiple publicly traded companies with pre-merger notification filings under the Hart-Scott-Rodino Antitrust Improvements Act
  • Represented an NYSE-listed company in $200 million tender offer for outstanding debt securities
  • Represented an arranger of $500 million CLO-backed note issuance
  • Represented an arranger of $500 million repo-backed note issuance
  • Represented an NYSE-listed pharmaceutical manufacturer in the acquisition of abbreviated new drug applications (ANDAs) and related assets for two generic pharmaceutical drugs
  • Represented a publicly traded paper company in $400 million sale of a subsidiary
  • Advising generic pharmaceutical manufacturers on U.S. and cross-border development, supply and other commercial contracts
  • Represented an international pharmaceutical company which purchased ANDAs and related assets as part of an FTC ordered divestiture
  • Represented a connected home technology company in a structured credit facility secured by a IP special purpose vehicle
  • Represented a regional insurance broker in the sale of its assets to a national broker
  • Represented an international investment bank in two structured credit facilities secured by solar renewable energy credits
  • Represented multiple publicly traded corporations in PIPE transactions
  • Represented several private companies in preferred stock financings
  • Represented a private equity service provider in the sale of its assets to an international competitor
  • Represented a financial institution in the negotiation of an exclusive co-branded credit card agreement